MEDICUS PHARMA LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MEDICUS PHARMA LTD. (MDCX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 45.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-12
- MEDICUS PHARMA LTD. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares.
- MEDICUS PHARMA LTD. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 45.00K shares.
- MEDICUS PHARMA LTD. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 37.50K shares.
- MEDICUS PHARMA LTD. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 45.00K shares, a 60.00% decline from fiscal 2024.
- MEDICUS PHARMA LTD. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 112.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 45.00K shares 10-Q · filed 2026-08-12 | 82.50K shares derived: sum of 3 quarters · filed 2026-08-12 | |
| 2026-03-31 | 45.00K shares 10-Q · filed 2026-05-14 | 82.50K shares derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2025-12-31 | 37.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 45.00K shares 10-K · filed 2026-03-25 | ||
| 2025-09-30 | 7.50K shares 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | 112.50K shares 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |